Hans Schikan is former CEO of Prosensa, a biopharmaceutical company focusing on novel RNA modulating treatments for rare diseases like Duchenne muscular dystrophy. Prosensa was listed on NASDAQ (RNA) in June 2013. The company was acquired by BioMarin early 2015 for up to USD 840 mln. Before joining Prosensa, Hans worked at Genzyme for five years in various executive roles, including as Vice President for Global Marketing and Strategic Development of Genzyme’s product portfolio for rare genetic diseases. Prior to Genzyme, he spent 17 years at Organon, both at corporate level and in country operations which included assignments in Asia and Europe.
Hans is currently Chairman of the Board of Complix (Belgium), Board Member of Vicore Pharma (publ, Sweden), VectivBio (Switzerland) and Pharvaris (Netherlands). He is also Member of the Top Team of the Dutch Top Sector Life Sciences & Health (Netherlands). Previously he served on the boards of Wilson Therapeutics (acquired by Alexion), Therachon (acquired by Pfizer), Sobi, Asceneuron and Hansa Biopharma. He has a PharmD from Utrecht University.